Xtant Medical

INVESTORS

HomeInvestors

INVESTORS

Click here for Webcast
Xtant Medical Fourth Quarter 2025 Financial Results
 03/31/26  8:30 AM EDT

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.

 

 

 

Stock Quote

(Common Stock)
Price
Change (%)
Volume
Data as of  

Minimum 15 minutes delayed. Source: LSEG

Stock Chart

Recent News

Date Title  
Toggle Summary Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
BELGRADE, Mont., March 25, 2026 /PRNewswire/ --  Xtant Medical Holdings, Inc.  (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the fourth quarter and full
Toggle Summary Xtant Medical Finalizes Companion Spine Transactions
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.   (NYSE American: XTNT), a medical technology company focused on surgical
Toggle Summary Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.  (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark
Toggle Summary Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont. , Dec. 11, 2025 /PRNewswire/ --  Xtant Medical Holdings, Inc.
More
Upcoming Events
Date Event Details
03/31/26  8:30 AM EDT
Xtant Medical Fourth Quarter 2025 Financial Results
More

Receive Email Alerts

Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.